Palatin Technologies, Inc. (0KF3) Earnings Call Transcript & Summary

November 15, 2021

London Stock Exchange GB Health Care Biotechnology earnings 25 min

Earnings Call Speaker Segments

Operator

operator
#1

Good day, everyone, and welcome to the conference call on Palatin's operating results for the first quarter of fiscal year 2021. Please note that this call is being recorded. Before we get into our remarks, I want to point out that anything Palatin states which is not a historical fact could constitute a forward-looking statement. Such statements rest on assumptions that might or might not turn out to be correct, and actual results could differ materially from what is anticipated because of the various risks and uncertainties covered in the company's latest filings with the Securities and Exchange Commission. We ask that you weigh those risks and uncertainties carefully when evaluating these forward-looking statements and Palatin's prospects. At this point, I'll hand today's call to our host, Dr. Carl Spana, Palatin's President and Chief Executive Officer.

Carl Spana

executive
#2

Thanks. Morning, everyone, and thanks for joining the Palatin Technologies Q1 2022 call. This is Dr. Carl Spana, President and CEO of Palatin. Joining me today is Steve Wills, our Executive Vice President, Chief Financial Officer, and Chief Operating Officer at Palatin. During this call, we'll share updates on both finances and operations. At this point I'll hand things over to Steve, who will walk through the financial updates. Steve.

Steve Wills

executive
#3

Thank you, Carl, and good morning to all of you. When it comes to our R&D infrastructure, we've bolstered the R&D department by bringing in key appointees who've shown a high level of expertise within their respective fields, and this is meant to help move our development programs forward. Turning to Vyleesi, which holds FDA approval for treating hypoactive sexual desire disorder, or HSDD, in perimenopausal women, what we aim to do with this program is prove the product's value in the marketplace, with the objective of relicensing the U.S. rights to a committed women's healthcare company or entity. Our disciplined plan is producing favorable movement on the targeted value metrics. In the quarter that closed September 30, 2021, gross product sales for Vyleesi rose 18%. Net revenue rose 98%. Net revenue per prescription dispensed rose 45%, even though total prescriptions dispensed fell 13% versus the prior quarter that ended June 30, 2021. Market access, reimbursement coverage, and refill rates have each risen compared with the prior quarter ending June 30, 2021, as well as compared with the successive quarters that ended December 31, 2020, and March 31, 2021. Now for our overall operating results, and revenue in particular: total net revenues are made up of Vyleesi gross product sales, net of allowances and accruals. Vyleesi gross product sales for the quarter ending September 30, 2021, came to $1.4 million, with net product revenue of $159,482, versus gross product sales of $809,100 for the period from July 25 — the date Palatin regained North American rights to Vyleesi from AMAG — through September 30, 2020, with negative product revenue of $288,560 for that September 30, 2020 period.

Steve Wills

executive
#4

On the operating expense side, total opex for the quarter that closed September 30, 2021, came in at $7.4 million, versus $3.7 million in the comparable quarter of 2020. Turning to cash flows, net cash used in operations at Palatin for the quarter ended September 30, 2021, was $6.4 million, against net cash provided by operations of $3.8 million in the same period of 2020. On net loss, Palatin posted a net loss of $7.1 million, or $0.03 per basic and diluted common share, for the quarter ended September 30, 2021, versus a net loss of $3.9 million, or $0.02 per basic and diluted common share, in the same period of 2020. Those variations in operating expenses, cash flows, and net loss between the quarters ended September 30, 2021, and 2020 stemmed mainly from the $1.6 million gain in the September 30, 2020 quarter, which lowered the expenses recorded in that quarter, and in particular from the Vyleesi termination agreement with AMAG. A secondary factor was higher commercial expenses tied to Vyleesi. As for cash position, at September 30, 2021, Palatin held $53.4 million in cash and cash equivalents, along with roughly $900,000 of accounts receivable, compared with cash and cash equivalents of approximately $60.1 million and $1.6 million of accounts receivable as of June 30, 2021.

Steve Wills

executive
#5

Given the operating plan we have in place right now, we think our current cash and cash equivalents will be enough to cover anticipated operating expenses through calendar year 2022. To put it plainly, that plan does account for the full set of expenses tied to Palatin's major inflection points — the data readout from our phase III dry eye disease trial and the data readout from our planned phase II ulcerative colitis trial, with both expected in the second half of calendar 2022. With that, I'll hand the call back to Carl.

Carl Spana

executive
#6

Thanks, Steve. I’ll say just a few things about Vyleesi. With Steve at the helm, we’re still achieving solid gains on the core value metrics that underpin Vyleesi’s commercial worth: net revenue rose 98%, and net revenue per prescription climbed 45%, compared with the June quarter. Our aim is to relicense Vyleesi to a dedicated partner so that it remains available as a treatment option for premenopausal women who have hypoactive sexual desire disorder. We’re still talking with prospective partners in the U.S. and other territories, and when a possible license happens really hinges on our getting acceptable terms with the right partner. Now let’s go on. In many inflammatory and autoimmune diseases, there’s still a critical medical need for novel therapies that give patients and clinicians safe and effective choices. Our R&D efforts center on moving forward a new treatment modality for patients with pathological inflammation, chiefly targeting ophthalmic diseases like diabetic retinopathy, dry eye and uveitis, by drawing on our distinctive knowledge and know-how in creating drugs that modulate the melanocortin system. A lot of today’s therapies for inflammatory and autoimmune conditions act by blocking one or more pro-inflammatory pathways, and that may lead to immune suppression and significant safety issues.

Carl Spana

executive
#7

Beyond that, for a lot of patients the efficacy diminishes as time goes on. To make progress in treating people who have inflammatory and autoimmune diseases, we strongly need new mechanisms of action that can produce effective treatments with improved safety. The melanocortin system is among the body's built-in mechanisms for resolving inflammation, bringing the immune system back to a normal state, and encouraging tissue healing. Our belief is that therapeutics activating the melanocortin system will be highly differentiated, delivering efficacy together with a superior safety profile. We have a plan with multiple layers, designed to move forward our understanding of how the melanocortin system operates at a molecular level and to provide clinical validation of melanocortin-based therapeutics. Should this succeed, we will have created a new class of therapeutics for treating inflammatory and autoimmune diseases. Our research scientists are employing the most recent genomic, proteomic, and cell biological technologies to push forward our fundamental understanding of how the melanocortin system resolves inflammation and promotes tissue healing. Results from these activities are already helping to guide our clinical development programs, and we look forward to communicating them via scientific publications and presentations in 2022. Our clinical development programs are mainly focused on developing melanocortin-based treatments for ocular indications.

Carl Spana

executive
#8

But we're also running small proof-of-concept trials in non-ocular indications. The purpose of these trials is to advance the broad usefulness of the melanocortin system as a fresh target for drug development and to bolster our technology licensing efforts. Naturally, our ultimate aim is the creation of new and differentiated therapeutics that deliver efficacy plus superior safety treatment options for patients. The melanocortin system is critically important in shielding the eye from damaging inflammation, and we are developing several melanocortin-based products for ocular diseases. PL9643, delivered topically, is our most advanced melanocortin agonist for treating ocular diseases affecting the tissues that make up the anterior segment, or the front of the eye. Dry eye disease is the first indication for PL9643, and as we have previously reported, we had positive data from a phase II dry eye disease clinical study. We held a successful end-of-phase II meeting with the FDA, at which we reached agreement on the key aspects of the PL9643 phase III clinical development program. Those include patient population, endpoints, and clinical trial design for the first of two phase III pivotal registration studies. MELODY-1 is the name of the first PL9643 phase III dry eye disease study, and it will evaluate the safety and efficacy of PL9643 versus vehicle control in patients with moderate to severe dry eye disease over a 12-week treatment period.

Carl Spana

executive
#9

This study aims to enroll 240 patients, and it incorporates an interim data assessment that an independent data monitoring committee will carry out. That assessment lets us raise the subject count if necessary, which lowers the risk of an underpowered study. Signs and symptoms of dry eye disease will make up the three co-primary and three key secondary endpoints, and we determined those endpoints from a detailed analysis of the phase II data. MELODY will begin in Q4 of calendar 2021, an interim data assessment will occur in the first half of calendar 2022, and we anticipate preliminary data in the second half of calendar 2022. If that goes well, we will launch the second phase III study in dry eye disease, known as MELODY-2, along with an open-label safety study called MELODY-3. If successful, the three MELODY PL9643 dry eye disease studies will supply the safety and efficacy data needed to file a New Drug Application with the FDA. PL9643's emerging profile — rapid therapeutic onset, excellent ocular tolerability, and safety — represents a potential distinct advance in dry eye therapy. Should the two phase II results be confirmed in the upcoming phase III clinical study, we believe PL9643 could achieve substantial penetration into the multibillion-dollar dry eye disease market.

Carl Spana

executive
#10

We also think PL9643, along with other melanocortin agonists, is going to be useful for treating several diseases at the front of the eye, and we're planning to start a clinical study in a second front-of-the-eye indication during calendar 2022. We haven't finalized which indication that study will target yet, but it will be grounded in our data and research. During the past year, we've also advanced considerably in our understanding of how promising it could be to target the melanocortin system against back-of-the-eye diseases, including diabetic retinopathy and macular edema. In preclinical models of retinal injury and diabetic retinopathy, our peptide PL9654, a melanocortin agonist, produced improvements in retinal morphology, shielded against photoreceptor cell loss and — importantly — preserved vision. The data on PL9654 support moving it into clinical development, and right now we're working to develop a sustained-release formulation of PL9654 that would be given through intravitreal injection, a standard technique for delivering drugs that treat retinopathies. The existing market for the various retinopathy drugs came to roughly $20 billion in 2021 and is expected to reach $27 billion by the end of 2025. A substantial need remains for innovative new retinal disease treatments, and we believe PL9654, even though it's early in development, holds tremendous potential to make a positive difference for patients with retinal disease and to expand our meaningful share of this very large market.

Carl Spana

executive
#11

Alongside the work we're doing in ocular research and clinical development, we've also been running a broad outreach campaign aimed at ophthalmologists and optometrists. Palatin scientists and collaborators have given presentations at the majority of the major medical meetings. We've been publishing our research actively as well. The presentation we gave on the protective effects of PL8331 and PL9654 in mouse models of retinopathy, delivered at the 2021 annual meeting of the American Society of Retina Specialists, earned a top 10 poster designation. Through these communication efforts, Palatin is being established as a community company that develops exciting new treatments for ocular diseases. Turning now to our oral formulation of PL8177 for ulcerative colitis, we're carrying out the activities needed to launch a phase II proof of concept study, which is targeted to begin patient enrollment in the first half of 2022, with initial data readout in the second half of 2022. This will be the first clinical study of ours designed to assess the potential of a selective melanocortin 1 receptor agonist as a treatment for ulcerative colitis. The study is going to evaluate the safety and potential efficacy of oral PL8177. Should the study's results be positive, they will add to the validation of the melanocortin system as a target for innovative drugs, as well as support our licensing efforts for PL8177.

Carl Spana

executive
#12

When it comes to drugs that target or treat the different inflammatory bowel diseases, that market is worth multiple billions of dollars, and there's still a substantial need for new options that are both safe and effective so treatment for these patients can be broadened and improved. If the safety and efficacy profile emerging for oral PL8177 holds up, it could represent a potential major step forward for inflammatory bowel disease treatment, especially among pediatric patients. Our natriuretic peptide program keeps moving our drug candidate PL3994 forward — a selective natriuretic peptide receptor-A agonist now being evaluated in a phase IIa clinical study involving heart disease patients with preserved ejection fraction. That clinical study is running in cooperation with a major academic center and receives support from a grant provided by the American Heart Association. Enrollment is ongoing, and we expect preliminary data in early 2022. More details about our research and development programs are available on our website, palatin.com. To close, a little over a year ago, when Vyleesi came back to us, we were a company with one female health product plus early but very interesting preclinical programs. Now, as we begin calendar 2022, we are a different company, advancing a new mechanism for treating a variety of inflammatory and autoimmune diseases based on drugs that modulate the melanocortin system, with a focus on ocular diseases.

Carl Spana

executive
#13

The first drug we have that's based on ocular melanocortin, PL9643, is going to begin a phase III study in dry eye disease before the end of the calendar year, and we're moving PL9654 forward in the drug development process as a therapy for retinal diseases. Each of these innovative drugs could become a meaningful participant in multi-billion-dollar markets that are expanding. We also intend to bring a second front-of-the-eye program into clinical studies during 2022. What underpins this transformation is a distinctive grasp of the melanocortin system plus expertise in developing drugs that modulate that system and in getting them approved. During the last year, we've established the infrastructure, the scientists, and the research efforts that are deepening our knowledge of the way the melanocortin system operates, and those results are already starting to inform our clinical programs. We're still on schedule to launch a phase II proof of concept clinical study using an oral formulation of PL8177 in patients with ulcerative colitis during the first half of 2022, with data readout in the second half of 2022. With Steve leading the way, our commercial work on Vyleesi has achieved substantial progress, and those changes are starting to produce a favorable effect on rising Vyleesi prescriptions and revenue, and we're actively working to license Vyleesi to a dedicated partner.

Carl Spana

executive
#14

To wrap up, our sights are set on 2022. Steve and I feel a great deal of enthusiasm about the huge chance before us to push forward a portfolio of innovative drugs that are highly differentiated, which will make a positive difference for patients and create shareholder value. We want to thank you for tuning in to our call and for your ongoing backing. At this point we'll open things up for questions.

Operator

operator
#15

Ladies and gentlemen, if you'd like to ask a question right now, please indicate by pressing star one on your telephone keypad. Kindly ensure that the mute function on your phone has been turned off so that your signal can reach our equipment. Our first question now comes from Joe Pantginis of H.C. Wainwright. Please go ahead.

Joe Pantginis

analyst
#16

Hey, guys. Morning. Thanks for taking the question. A couple, if you don't mind. First, I know it's hard to predict, but, you know, with regard to Vyleesi, can you at least describe, I guess, the maturity of these discussions and the tenor of the discussions?

Steve Wills

executive
#17

Sure. Hey, Joe, this is Steve. We’re not going to get into that level of detail, if you will, about the discussions. We’re talking with several companies, and those conversations are at different stages. What I can say is that the progress we’ve made over the past few quarters has been substantial, and frankly it has led to better discussions. It’s really similar to drug development: you go through phase I, phase II, you establish safety and proof of concept, and then you advance. We’re demonstrating those metrics. We’re quite pleased with what we highlighted today, given the limited investment we’ve been able to make and still achieve this kind of progress. To put that in context, Joe, when we took over in late July of 2020, fewer than 5% of scripts were running through with insurance being reimbursed. At this point we’re above 40%. We actually had negative—I’m not stuttering—negative net product revenue. Now we have positive net product revenue. Very importantly, revenue per dispensed script has risen significantly. That’s really the holy grail, which is to get your... You know, if you have a model in which insurance reimbursement is very significant, which ours is, because we have a very good WAC, the higher the amounts you get in that area, frankly, obviously the higher the amounts you’re going to get for net revenue.

Steve Wills

executive
#18

We have been focusing on those areas, and those areas are definitely paying off. Again, the discussions are frankly stronger simply because we can demonstrate that kind of activity. Our metric is not to grow the scripts. Are we okay if scripts go up? Absolutely. We're not — we don't have a sales force. We're not spending the kinds of monies that other companies you're very aware of, say, in the female healthcare space are spending, you know, whether it's DTC, digital, social media, whatever. We're pleased that the metrics we targeted with our limited investment are beginning to show very positive trends. You know, from a timing standpoint, we've talked about it being done by the end of the year. You know, we've adjusted that guidance a little bit in that we think it could very well roll into the first half of 2022. That's our objective, and it's a timing difference. We're always data-driven, we're not date-driven. We wanna make sure we have the right partner, and frankly, give Vyleesi the attention it needs. Let me pause there. Is that responsive enough, Joe?

Joe Pantginis

analyst
#19

Oh, it definitely is. Thanks for the detail, Steve. I think my next two questions tie together somewhat, you know, but the real focus is on what I'd call your really widening efforts across the melanocortin platforms, and you folks are quite busy. I suppose when it comes to all of your work, whether for nine six four three or your other assets, where do you stand with, say, formulation work for assets as well as development and manufacturing readiness?

Carl Spana

executive
#20

Sure. So for PL9643, we're basically at the point of releasing drug product out to the clinical trial sites. The format is quite straightforward — a small single-use plastic blow-fill-seal dispenser that delivers the single dose of the drug. That technology is very well-established, and we're certainly on track to have validated manufacturing in place that supports phase III. Then, while we're running phase III, we'll be working on putting the final commercial setup in place. More importantly — and this is probably closer to where you were headed with 9643 — 9654, sorry, for the retinopathies, which is really where we are. I can't tell you how excited we are about that product. I mean, what it's doing and how it's performing preclinically — I mean, if we can pull that off in the clinic, it's going to be great. We're pretty fortunate there. We should be getting the first formulation data in soon for us to take a look at. Because the drug is an agonist and we're dosing relatively low, so we don't need to load the eye up with drug, the expectation — and what we've seen so far — is that it will behave pretty much like the vehicle carriers. We're quite bullish that, as we get into the beginning of the year, we'll have a formulation that can begin animal testing.

Carl Spana

executive
#21

Around mid-year, we're hoping to get that truly progressing into preclinical work, safety and so forth, and on to patients. We view that as fairly low risk, though obviously one we're pressing hard on. And then last, the oral piece again — for PL8177, also a peptide — and there we're delivering it to the colon and the GI tract. Through oral delivery of that formulation, we're treating the lumen. I'd call it suitable for where it sits in development. Our CMO and the manufacturing team are collaborating with vendors to get beyond the phase II formulation and put in place a much better, more robust manufacturing process to support licensing once that data arrives. I think we're in good shape there overall, and the team is working quite hard on it. As you know, we're experienced in setting up manufacturing for commercialization, given what we've done with Vyleesi.

Joe Pantginis

analyst
#22

Right. Actually, I’ll borrow something from one of your comments about PL9654 and what you’re doing with it as a bit of a bridge into my final point. So, on the subject of being so busy: once the formulation for PL9654 is developed, how fast do you figure you could realistically move into back of the eye disorders — or how fast would you want to — given the punch list you’re working from right now?

Carl Spana

executive
#23

I mean, it's certainly going to shift into early 2023. If we're — let me phrase it this way — if we're in good shape by the middle of the year, mid-2022, which I believe we will be, then we'll have. You know, filing an IND takes roughly nine months. Naturally, you know, since the retinopathy space is quite big and large players dominate it, we'll be actively seeking partnership talks all through the development of PL9654. Of course, you can never be certain when a deal will get done, but we definitely want to. You know, we'll keep pushing that forward because, you know, patients with the various retinopathies really do have current treatment options, mostly anti-VEGFs. They certainly work in some patients, but, you know, they don't treat every patient, and a very, very strong need remains. These patients will eventually lose their sight if they don't receive treatment. Even those on current treatment, you know, as time passes, the efficacy does diminish. There's a very, very strong need, and it's simply astounding how big that market is. You know, $27 billion by 2025. I mean, that's a large market we're going after.

Carl Spana

executive
#24

I'm certain that at some point we're going to need some assistance, and we want to be sure that, you know, we have it in place.

Joe Pantginis

analyst
#25

Understood. Appreciate the additional detail, everyone.

Steve Wills

executive
#26

Absolutely, Joe. Appreciate it.

Operator

operator
#27

Thank you. Are there any further questions? Nikhil would like to give the call back to Dr. Carl Spana so he can offer any additional or closing remarks.

Carl Spana

executive
#28

Thanks. I want to express my appreciation to everyone for joining us on this call covering fiscal Q1 2022. Calendar 2022 is a significant year for our company. We have numerous clinical readouts coming. Several items that we have not yet shared with you will likely be shared on our next phone call, and those are pretty exciting developments. We honestly could not be more thrilled here. The teams are truly, you know, producing at a high rate, and we are going to have plenty of milestones and accomplishments next year. Having said that, enjoy your day, your end of the year celebrations and holidays, and we will speak with you soon.

Operator

operator
#29

Thanks. That brings us to the end of today's conference call. We appreciate everyone joining us. Ladies and gentlemen, you're free to disconnect now.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Palatin Technologies, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Palatin Technologies, Inc. earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Palatin Technologies, Inc. or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.